Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,549,863
  • Shares Outstanding, K 122,265
  • Annual Sales, $ 18,470 K
  • Annual Income, $ -589,530 K
  • EBIT $ -573 M
  • EBITDA $ -563 M
  • 60-Month Beta 0.58
  • Price/Sales 417.68
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 52.66% (-0.79%)
  • Historical Volatility 39.35%
  • IV Percentile 21%
  • IV Rank 11.65%
  • IV High 110.92% on 04/09/25
  • IV Low 44.98% on 01/22/25
  • Expected Move (DTE 17) 5.04 (8.28%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 438
  • Volume Avg (30-Day) 2,900
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 117,880
  • Open Int (30-Day) 115,109
  • Expected Range 55.82 to 65.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.48
  • Number of Estimates 10
  • High Estimate -0.20
  • Low Estimate -2.14
  • Prior Year -1.26
  • Growth Rate Est. (year over year) -17.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.37 +2.57%
on 12/17/25
70.98 -14.21%
on 12/22/25
-7.23 (-10.62%)
since 11/28/25
3-Month
53.61 +13.59%
on 10/01/25
70.98 -14.21%
on 12/22/25
+5.94 (+10.80%)
since 09/30/25
52-Week
29.31 +107.76%
on 05/15/25
70.98 -14.21%
on 12/22/25
+13.74 (+29.15%)
since 12/30/24

Most Recent Stories

More News
Cytokinetics Announces FDA Approval of MYQORZOâ„¢ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First...

CYTK : 60.99 (-1.23%)
Stocks Settle Higher on Upbeat Tech Outlook and Cooling Inflation

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up by +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +1.51%. December...

AMAT : 261.45 (-0.61%)
GOOGL : 313.62 (+0.02%)
CNK : 23.04 (-0.30%)
AAPL : 272.96 (-0.29%)
SNDK : 243.69 (-0.23%)
MRK : 106.05 (-0.53%)
$IUXX : 25,519.41 (-0.02%)
ASML : 1,077.29 (+1.06%)
DJT : 12.83 (-2.51%)
ZNH26 : 112-210 (-0.06%)
MSFT : 488.46 (+0.28%)
TSLA : 460.09 (+0.10%)
Stocks Rally as Chip Makers Soar and US Price Pressures Ease

The S&P 500 Index ($SPX ) (SPY ) today is up by +1.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.82%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +1.91%. December E-mini S&P futures...

MSTR : 157.35 (+1.26%)
AMAT : 261.45 (-0.61%)
GOOGL : 313.62 (+0.02%)
CNK : 23.04 (-0.30%)
AAPL : 272.96 (-0.29%)
SNDK : 243.69 (-0.23%)
GLXY : 22.95 (-0.91%)
MRK : 106.05 (-0.53%)
$IUXX : 25,519.41 (-0.02%)
COIN : 234.20 (+0.18%)
ASML : 1,077.29 (+1.06%)
DJT : 12.83 (-2.51%)
Stocks Rebound on Strength in Chip Stocks and a Benign US CPI Report

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +1.43%. December E-mini S&P futures...

MSTR : 157.35 (+1.26%)
AMAT : 261.45 (-0.61%)
CNK : 23.04 (-0.30%)
SNDK : 243.69 (-0.23%)
GLXY : 22.95 (-0.91%)
MRK : 106.05 (-0.53%)
$IUXX : 25,519.41 (-0.02%)
COIN : 234.20 (+0.18%)
ASML : 1,077.29 (+1.06%)
DJT : 12.83 (-2.51%)
ZNH26 : 112-210 (-0.06%)
ESH26 : 6,951.50 (-0.05%)
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Approval Triggers Milestone Payment of $7.5 Million from Sanofi;  Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO,...

CYTK : 60.99 (-1.23%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 15, 2025 it granted stock options to purchase an aggregate of...

CYTK : 60.99 (-1.23%)
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee...

CYTK : 60.99 (-1.23%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted...

CYTK : 60.99 (-1.23%)
CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

NEW YORK , Nov. 17, 2025 /PRNewswire/ --

CYTK : 60.99 (-1.23%)
CYTK LAWSUIT ALERT: Levi & Korsinsky Notifies Cytokinetics, Incorporated Investors - Lead Plaintiff Deadline November 17, 2025

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ: CYTK) investment and want to learn about a potential recovery under the federal...

CYTK : 60.99 (-1.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 63.58
2nd Resistance Point 63.15
1st Resistance Point 62.45
Last Price 60.99
1st Support Level 61.32
2nd Support Level 60.89
3rd Support Level 60.19

See More

52-Week High 70.98
Last Price 60.99
Fibonacci 61.8% 55.06
Fibonacci 50% 50.15
Fibonacci 38.2% 45.23
52-Week Low 29.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar